Power of the five methods for different proportions () of associated SNPs within a pathway of size 60.

<p>Plots illustrate the power of the methods when the total number of associated SNPs equals 100 (plot (A)) and 200 (plot(B)), the effect sizes are and for both plots.</p

Pairwise scatterplot of power for the five methods across all simulated non-null scenarios.

<p>Pairwise scatterplot of power for the five methods across all simulated non-null scenarios.</p

Mean power of the methods for the different pathway sizes.

<p>The mean power of the methods is computed for all the scenarios for the three different tested pathway sizes across all other variables.</p

Mean power of the methods that have a type-I error 5% across all simulated scenarios.

<p>Mean power of the methods across all simulated scenarios.</p

Power of the methods for the different pathway sizes.

<p>Power of the methods for the different pathway sizes.</p

Pathway Analysis of BMI.

<p>Table shows the nominal p-values of all five methods for the Biocarta VIP pathway. Biocarta VIP pathway has been reported as being significantly associated with BMI and the risk of obesity.</p

Performance of the methods when applied on the data of the GWAS.

<p>Table shows the method that identifies the largest number of pathways with nominal p-value less than 0.05 for each phenotype and database. The numbers in the brackets represent the number of enriched pathways identified by the equivalent method divided by the total number of enriched pathways identified by all the tested methods.</p

Power of the methods as the proportion of pathway SNPs with effects changes.

<p>Power of the methods for a pathway of size 20. 50 genes in total have effects. The effect size of the pathway genes is 4 and the effect size of the rest of the genes is 1.</p

Power of the five methods for different pathway sizes.

<p>Plots illustrate the power of the methods when the total number of associated SNPs equals 100, the proportion of associated SNPs within each pathway is 0.4 and the effect sizes are and .</p

<i>In vivo</i> morpholino screen in zebrafish identifies 15 new regulators of thrombopoiesis.

<p>MOs were injected into one-cell stage transgenic <i>Tg(cd41:EGFP)</i> zebrafish embryos and assayed for their effect on the number of thrombocytes (<i>cd41^high</i>) at 3 dpf. Representative confocal images were taken of the CHT. For <i>akap10</i>, <i>brd3a</i>, <i>brf1b</i>, <i>kalrn 1</i>, <i>kalrn 2</i>, <i>kif1b</i>, <i>mfn2</i>, <i>pdia5</i>, <i>psmd13</i> and <i>satb1</i> a severe decrease in the number of <i>cd41^high</i> positive cells was observed. <i>brf1a</i>, <i>rcor1</i>, <i>waspla</i>, <i>wasplb</i> and <i>wdr66</i> depletion resulted in a mild phenotype, and <i>fen1</i>, <i>grtp1b</i> and <i>tmcc2</i> MO injected embryos showed no phenotype. All embryos are oriented with anterior to the left and dorsal to the top. White arrow – thrombocytes; white arrowhead – HSCs.</p